Developing Interventions for Protecting HIV-Exposed Uninfected Infants Against Severe Infections
NCT ID: NCT07052409
Last Updated: 2025-07-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
72 participants
INTERVENTIONAL
2025-04-10
2029-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
B. Infantis Supplementation to Improve Immunity in Infants Exposed to HIV
NCT05923333
Long-Term Effects of HIV Exposure and Infection in Children
NCT00006304
Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission
NCT00028145
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
NCT06517693
HIV Exposure in Utero and Metabolic Disease Risk in HIV-Negative Young Adults
NCT04132830
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. The study will enroll 24 HIV-exposed uninfected infants (HEU) at 24 weeks of age and randomize them 1:1 to receive ≥15 ml daily of pasteurized fermented milk (Inkomasi) or not. Changes in infant gut microbiota from enrollment to 4 weeks after enrollment will be compared between groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Inkomasi
Diet supplementation with pasteurized fermented milk
Inkomazi
Pasteurized fermented milk
Control
No intervention
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inkomazi
Pasteurized fermented milk
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
6 Months
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adriana Weinberg
Professor of Pediatrics, Medicine and Pathology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adriana Weinberg, MD
Role: PRINCIPAL_INVESTIGATOR
AMC UCD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Witwatersrand
Johannesburg, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-1383 COMIRB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.